European Commission set to simplify EMA fees framework in major overhaul

EMA Blog Regulatory Affairs

The European Commission recently that it would overhaul the framework for fees payable to the European Medicines Agency (EMA) to simplify application of the fee system for industry. Under Article 67(3) of the  regulation, fees and charges are part of the revenue needed to assessment and authorization of new medicines, for the development and access of new medicines, and for the maintenance and monitoring of EU approved medicines.

However, the framework governing the fee system has become complex due to the different categories and types of fees levied, making it challenging to manage it effectively. The revision seeks to address this issue as well as misalignment of some fees and the associated underlying costs, lack of fees or national competent authority remuneration for some procedural activities, and some discrepancies between the EMA Fee Regulation and the Pharmacovigilance Fee Regulation.

The agency has said the overhaul seeks to provide a “sound financial basis to support the EMA’s operations, including remuneration for services to the EMA rendered by national competent authorities, in line with the applicable legislation”.

Another important objective is to future-proof the fee system by bringing in flexibility with regards to how it is adjusted.

The revision also provides for an amendment to Article 106 of the Medical Devices Regulation in anticipation of fees payable to the EMA for advice the agency provides the secretariat for the expert panels.

An impact assessment process canvassed the main stakeholder groups via a survey, with four potential ways to overhaul the system. The surveys were followed by a series of targeted interviews with national competent authorities, the Heads of Medicines Agencies and the EMA.

After the consultation process, it was proposed that minor post-authorization activities be included in the annual fee for products authorized through the centralised procedure, while major post-authorization procedures should still attract a separate fee. This proposal was out for public consultation until February 2023 and a date for the regulation update has not yet been announced. The expectation is that the overhaul will make the fees not only less complex but also more predictable.







Scroll to Top

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from Should you receive an email and are unsure as to its validity, please report it to

Many thanks for your understanding.

The PharmaLex Team